Evidence map›Paper›PMID 40693755›Full record

Trial reportNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2025

Characteristics of Black Adults Who Never Achieved 24-Hours of Abstinence in a Smoking Cessation Trial: Implications for Improving Treatment Response.

Archana N Sundar, Lisa Sanderson Cox, Eleanor L S Leavens, Alexandra Brown, Matthew S Mayo, Jasjit S Ahluwalia, Nicole L Nollen

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Archana N SundarDepartment of Population Health, University of Kansas School of Medicine, Kansas City, KS.ORCID 0009-0005-8124-8212
Lisa Sanderson CoxDepartment of Population Health, University of Kansas School of Medicine, Kansas City, KS.
Eleanor L S LeavensDepartment of Population Health, University of Kansas School of Medicine, Kansas City, KS.ORCID 0000-0003-2948-2384
Alexandra BrownUniversity of Kansas Cancer Center, University of Kansas School of Medicine, Kansas City, KS.
Matthew S MayoUniversity of Kansas Cancer Center, University of Kansas School of Medicine, Kansas City, KS.
Jasjit S AhluwaliaDepartment of Behavioral and Social Sciences and the Center for Alcohol and Addiction Studies, Brown University of Public Health, Providence, RI.
Nicole L NollenDepartment of Population Health, University of Kansas School of Medicine, Kansas City, KS.

Funding

Transgenic & Gene-Targeting Shared ResourceP30CA168524 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ROY A. JENSEN · 2012 to 2026
$40.1M
Using wearables and EMA to examine the links between cannabis and depressionP20GM130414 · NIGMS · BROWN UNIVERSITY · PI Cara Murphy · 2019 to 2026
$22.0M
Heartland Institute for Clinical and Translational ResearchUL1TR000001 · NCATS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI BAROHN, RICHARD J. · 2012 to 2015
$13.0M
Understanding the Impact of Marijuana and Opioid Misuse on Tobacco Dependence Treatment and Outcomes among African American Participants in a Clinical TrialR01DA046576 · NIDA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI NOLLEN, NICOLE L · 2018 to 2022
$3.6M
National Institutes of Health National Center for Advancing Translational Science UL1TR000001NCATS NIH HHS UL1 TR000001NCI NIH HHS P30 CA168524NIDA NIH HHS R01 DA046576NIH HHS P20GM130414
6 · The paper itself

Abstract

introductionMaximizing early treatment response is an important strategy for long-term abstinence, yet little is known about individuals who never achieve any period of abstinence. Improving early treatment response is critical for Black adults who smoke (AWS) who bear a disproportionate share of tobacco-related mortality.

methodsSecondary data analysis of a randomized clinical trial among Black AWS (N = 392) interested in quitting smoking. Participants received 18 weeks of pharmacotherapy and smoking cessation counseling. This investigation quantified the proportion of participants who never achieved 24-hour abstinence through week 2 (W2). Best subsets logistic regression identified baseline and non-baseline factors contributing to never achieving 24-hour abstinence.

results135 participants (36.2%) did not achieve 24-hour abstinence by W2 despite good adherence with nicotine patch (73.9% had > 80% compliance). Of those, 56.4% and 47.8% still did not achieve 24-hour abstinence at W6 and W12, respectively. Baseline financial strain, higher baseline cotinine and smoking more CPD at W2 increased odds of never achieving 24-hour abstinence while greater cessation self-efficacy and more positive beliefs about study medication at W2 decreased odds of never achieving 24-hours abstinence.

conclusionsA substantial proportion of individuals who were motivated to quit smoking and received gold-standard treatment (i.e., pharmacotherapy and counseling) never achieved a period of 24 hours of abstinence. Findings highlight financial strain, nicotine dependence, early self-efficacy challenges, and medication experience as targets for improving abstinence among those at high risk for early treatment failure. By characterizing a subset within a larger population at-risk of continued smoking, the study presents opportunities to consider contributors to treatment success. IMPLICATIONS: Individuals who do not experience success with quitting early in treatment rarely go on to achieve long-term abstinence, yet the majority of interventions fail to address challenges among this high-risk subgroup. Findings suggest a need for interventions that consider the psychological impact of unmet social needs associated with financial strain, address low cessation self-efficacy, and early experiences with smoking cessation pharmacotherapy as approaches for bolstering treatment efficacy. Two possible evidence-based interventions for addressing these factors are discussed.

Indexed as

Black or African AmericanSmoking CessationTobacco Use DisorderAdultCounselingFemaleHumansMaleMiddle AgedSelf EfficacySmoking Cessation AgentsTobacco Use Cessation DevicesTreatment OutcomeSmoking Cessation Agents

Identifiers

PMID40693755
PMCPMC12723230

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.